Apricus Biosciences, Inc. (NASDAQ:APRI) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02
Apricus Biosciences, Inc. (NASDAQ:APRI) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On November 18, 2016, Catherine Bovenizer tendered her resignation as Vice President, Chief Accounting Officer of Apricus Biosciences, Inc. (the “Company”), such resignation to be effective as of December 1, 2016. Ms. Bovenizer serves as the Company’s principal accounting officer. Ms. Bovenizer resigned to pursue other opportunities and she will not receive any severance payments under her employment agreement in connection with her departure. Ms. Bovenizer’s departure is not due to a dispute or disagreement with the Company.
The Company does not intend to recruit a replacement for Ms. Bovenizer as the Company believes it can address its accounting and financial reporting requirements using its existing internal resources. Richard W. Pascoe, the Company’s Chief Executive Officer and Secretary, will serve as the Company’s principal accounting officer.
* * *
About Apricus Biosciences, Inc. (NASDAQ:APRI)
Apricus Biosciences, Inc. is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company’s drug delivery technology is a permeation enhancer called NexACT. The Company has over two product candidates in Phase II development, fispemifene for the treatment of symptomatic male secondary hypogonadism and RayVa for the treatment of Raynaud’s phenomenon, secondary to scleroderma. The Company has a commercial product, Vitaros for the treatment of erectile dysfunction (ED), which is in development in the United States, approved in Canada and marketed throughout Europe. Apricus Biosciences, Inc. (NASDAQ:APRI) Recent Trading Information
Apricus Biosciences, Inc. (NASDAQ:APRI) closed its last trading session down -0.08 at 1.63 with 62,620 shares trading hands.
Apricus Biosciences, Inc. is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company’s drug delivery technology is a permeation enhancer called NexACT. The Company has over two product candidates in Phase II development, fispemifene for the treatment of symptomatic male secondary hypogonadism and RayVa for the treatment of Raynaud’s phenomenon, secondary to scleroderma. The Company has a commercial product, Vitaros for the treatment of erectile dysfunction (ED), which is in development in the United States, approved in Canada and marketed throughout Europe. Apricus Biosciences, Inc. (NASDAQ:APRI) Recent Trading Information
Apricus Biosciences, Inc. (NASDAQ:APRI) closed its last trading session down -0.08 at 1.63 with 62,620 shares trading hands.
